Efficacy and Safety of SIL-8301 for Control of Hemolysis in a Uniform Sickle Cell Disease Endotype
Phase 2 · 4 sites
Search the registry
2,585 studies found
Phase 2 · 4 sites
76 sites
Phase 2 · 1 site
Potential match only. Final eligibility is determined by the study team.